Clinical Trial Search

Primary: Percentage of Participants With Reduction in Adverse Events — 94; 86; 73; 84 percentage of participants

Primary: Time to First Skeletal Related Event — 31.9; 28.8 months — p=0.385

Primary: Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS)…

Primary: Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) — -1.05…

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.43; 0.14; -1.33 percentage of HbA1c — p=<0.001

Primary: Fall-related Process Measures — 0.40; 0.32 proportion of indicators completed

Primary: Percentage of Change of TG (Triglyceride) — -30.6; 10.7; -27.3; -2.9 percentage of change

Primary: Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2 — -3.19; -3.16; -2.02 Score on a Scale — p=<0.001

Primary: Moderate Intensity Physical Activity: Modified Community Healthy Activities Model Program for Seniors (CHAMPS) Questionnaire — 37; 44 participants

Primary: Number of Days for Discontinue Assistive Devices — 28; 22 days — p=.04

Primary: Complete Response (CR) Rate — 0.68 proportion

Primary: Plasma Cathelicidin (hCAP18) Protein Levels at 48 Hours — 76; 82 ng/ml — p=0.25

Primary: Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST) — 3 percentage of participants

Primary: Response Rate — 34; 12.5 percentage of responding patients

Primary: Diabetes Treatment Satisfaction Questionnaire: Status (DTSQs) Score — 28.2; 31.5; 32.2; 34.2 units on a scale